Table 1.

Patient demographics and clinical data before the initiation of MTX (0 month), and after 3 and 6 months of therapy

Patient characteristics
Visit, months	0	3	6
No. of patients	66	51	34
Gender, female, no. (%)	48 (73)	33 (65)	22 (65)
Age, y, median [IQR]	11.5 [5.4, 14.4]	10.9 [5.3, 13.8]	10.3 [5.5, 13.9]
ESR, mm/h	16 [9, 35]	9 [7, 21]***	8 [7, 15]***
CRP, mg/L	0.7 [0.5, 1.8]	0.5 [0.5, 1.3]*	0.5 [0.5, 0.6]*
AJC	5 [2, 13]	3 [1, 7]***	1 [0, 5]***
PT‐VAS	6 [3, 8]	2 [0.8, 4]***	1 [0.5, 4]***
MD‐VAS	5 [3, 7]	2 [0, 4]***	1 [0, 2.5]***
CHAQ	0.5 [0.1, 1.4]	0.12 [0, 0.66]***	0 [0, 0.25]***
JADAS	19 [12, 30]	7 [4, 16.5]***	5 [2, 10.15]***
ACR Pedi <30, no. (%)	–	15 (29)	5 (15)
ACR Pedi >30, no. (%)	–	36 (71)	29 (85)
ACR Pedi >50, no. (%)	–	27 (53)	27 (79)
ACR Pedi >70, no. (%)	–	14 (27)	18 (53)

ACR Pedi, American College of Rheumatology pediatric response criteria; AJC, active joint count; CHAQ, Childhood Health Assessment Questionnaire; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; JADAS, 71‐joint count Juvenile Arthritis Disease Activity Score; MD‐VAS, physician global assessment of disease activity visual analogue scale; PT‐VAS, physician global assessment of disease activity visual analogue scale.

*p < 0.05; **p < 0.01; ***p < 0.001 by paired Wilcoxon signed‐rank testing.